News
-
-
-
COMMUNIQUÉ DE PRESSE
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment for inflammatory bowel disease. SIM0709, a novel bispecific antibody, aims to improve outcomes for patients worldwide